Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Alaunos Therapeutics (TCRT) over the last 11 years, with Q3 2025 value amounting to -$0.55.

  • Alaunos Therapeutics' EPS (Weighted Average and Diluted) rose 2142.86% to -$0.55 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.31, marking a year-over-year increase of 6861.41%. This contributed to the annual value of -$3.01 for FY2024, which is 8632.16% up from last year.
  • According to the latest figures from Q3 2025, Alaunos Therapeutics' EPS (Weighted Average and Diluted) is -$0.55, which was up 2142.86% from -$0.63 recorded in Q2 2025.
  • Over the past 5 years, Alaunos Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.04 during Q3 2022, and registered a low of -$5.49 during Q2 2023.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.63 (2023), whereas its average is -$1.33.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 1315000.0% in 2023, then skyrocketed by 9037.74% in 2024.
  • Alaunos Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.06 in 2021, then tumbled by 4033.33% to -$2.48 in 2022, then tumbled by 97.58% to -$4.9 in 2023, then skyrocketed by 90.38% to -$0.47 in 2024, then fell by 16.65% to -$0.55 in 2025.
  • Its last three reported values are -$0.55 in Q3 2025, -$0.63 for Q2 2025, and -$0.67 during Q1 2025.